Literature DB >> 28729746

The Incidence and Effects of Alloimmunization in Pregnancy During the Period 2000 - 2013.

Marjana Jerković Raguž1, Darinka Šumanovic Glamuzina1, Jerko Brzica1, Tonći Gruica2.   

Abstract

INTRODUCTION: The objective of the analysis was to examine the epidemiological aspects of maternal alloimmunization and to determine the most common antibody specificities resulting in hemolytic disease of the newborn (HDN).
MATERIALS AND METHODS: The retrospective epidemiological study encompasses all pregnant women who underwent immunohematological screening and the newborn treated for HDN in the period from 2000 to 2013 in the Herzegovina region.
RESULTS: The indirect Coombs test (ICT) detected antibodies against antigens in 384 (2.4%) pregnant women of the 18 800 who were tested at the Department of Transfusion Medicine. The direct Coombs test (DCT) detected antibodies against antigens in 160 (0.8%) newborn treated for HDN. The results of our 13-year study, in which 60% of the pregnant women had non-RhD antibodies, confirms this finding.
CONCLUSION: However, we have reached the 21st century and the burden of alloimmunisation in pregnancy is still on our backs. The problem of immunization and HDN is still present in our region, which is a neonatal and public health problem.

Entities:  

Keywords:  hemolytic disease; newborn; sensitization

Year:  2017        PMID: 28729746      PMCID: PMC5514019          DOI: 10.1055/s-0043-109867

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  18 in total

1.  Prevalence of clinically significant red blood cell alloantibodies in pregnant women at a large tertiary-care facility.

Authors:  Heather M Smith; Rosetta S Shirey; Sandra K Thoman; Jay B Jackson
Journal:  Immunohematology       Date:  2013

2.  Alloimmunization in pregnancy during the years 1992-2005 in the central west region of Sweden.

Authors:  Tomas Gottvall; Derek Filbey
Journal:  Acta Obstet Gynecol Scand       Date:  2008       Impact factor: 3.636

Review 3.  [Foetomaternal erythrocyte incompatibilities: from immunohaematologic surveillance of pregnant women to haemolytic disease of the newborn].

Authors:  E Miquel; B Cavelier; J C Bonneau; P Rouger
Journal:  Transfus Clin Biol       Date:  2005-02       Impact factor: 1.406

4.  Neonatal hyperbilirubinemia due to ABO incompatibility: does blood group matter?

Authors:  Sinem Akgül; Ayşe Korkmaz; Sule Yiğit; Murat Yurdakök
Journal:  Turk J Pediatr       Date:  2013 Sep-Oct       Impact factor: 0.552

5.  Risk of maternal alloimmunization in Southern Pakistan - a study in a cohort of 1000 pregnant women.

Authors:  Farheen Karim; Bushra Moiz; Nausheen Kamran
Journal:  Transfus Apher Sci       Date:  2014-12-11       Impact factor: 1.764

6.  Management of pregnancies complicated by anti-E alloimmunization.

Authors:  Saju D Joy; Karen Q Rossi; Dave Krugh; Richard W O'Shaughnessy
Journal:  Obstet Gynecol       Date:  2005-01       Impact factor: 7.661

7.  [Kell immunization--a case report].

Authors:  Marija Tasić; Jelena Milosević; Milan Stefanović; Dragana Radović-Janosević; Miljan Krstić; Vladimir Antić
Journal:  Med Pregl       Date:  2009 Jul-Aug

8.  Exchange Transfusion for Severe Neonatal Hyperbilirubinemia: 17 Years' Experience from Vojvodina, Serbia.

Authors:  Nevenka Bujandric; Jasmina Grujic
Journal:  Indian J Hematol Blood Transfus       Date:  2015-04-02       Impact factor: 0.900

9.  Is antibody screening in Rh (D)-positive pregnant women necessary?

Authors:  S Lurie; E Eliezer; I Piper; I Woliovitch
Journal:  J Matern Fetal Neonatal Med       Date:  2003-12

10.  Correlation between the Amount of Anti-D Antibodies and IgG Subclasses with Severity of Haemolytic Disease of Foetus and Newborn.

Authors:  Emilija Velkova
Journal:  Open Access Maced J Med Sci       Date:  2015-05-30
View more
  1 in total

1.  An Unusual Case of Hemolytic Disease of Newborn Due to ABO and Rh Isoimmunization.

Authors:  Suman S Routray; Jagdish P Sahoo; Rachita Behera; Devi Acharya; Girija N Kanungo
Journal:  Cureus       Date:  2020-12-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.